Page 1 of 3

Replagal for the treatment of Fabry disease

Replagal is a solution for infusion into the body containing the active substance Agalsidase alfa. Replagal is used to treat patients who have Fabry disease, a rare inherited disorder. Patients with Fabry disease do not have enough of an enzyme, alpha-galactosidase A. This enzyme normally bre...
Read Article

Rosiglitazone and Pioglitazone: cardiovascular safety

Rosiglitazone (Avandia, Avandamet ) and Pioglitazone ( Actos, Competact ) are treatments for patients with type 2 diabetes and belong to a class of drugs called thiazolidinediones ( also called glitazones ). Concerns have arisen about the cardiovascular safety of thiazolidinediones: heart failur...
Read Article

Pioglitazone and Rosiglitazone may reduce bone density

Thiazolidinediones include Rosiglitazone ( Avandia and Avandamet ) and Pioglitazone ( Actos ). These medicines act to increase insulin sensitivity and are widely prescribed to treat type II diabetes mellitus. Recent evidence suggests thiazolidinediones are associated with an increased risk of peri...
Read Article

Novartis has proposed improving Galvus risk/benefit profile through use of approved 50 mg once-daily and twice-daily doses instead of approved 100 mg once-daily

Novartis has provided a safety update to European regulators of pooled data showing numerically less frequent liver enzyme elevations in patients who took either 50 mg per day or 50 mg twice daily of Galvus ( Vildagliptin ) compared to 100 mg once-daily. As a result, Novartis has proposed changes to...
Read Article

Pioglitazone appears to have overall favorable effect regarding risk of cardiovascular events

A meta-analysis of previous research suggests that use of Pioglitazone ( Actos ), a glycemic control medication for patients with type 2 diabetes, significantly reduces the risk of myocardial infarction, stroke and death, but increases the risk for serious heart failure. Michael A Lincoff and col...
Read Article

Heart failure risk: boxed warning for Pioglitazone and Rosiglitazone

The FDA ( Food and Drug Administration ) announced manufacturers, GlaxoSmithKline ( GSK ) and Takeda, of glitazones approved to treat type 2 diabetes, have agreed to add a stronger warning on the risk of heart failure. The information will be included in the form of a boxed warning, the FDA's strong...
Read Article

Avandia linked to risk of myocardial infarction and heart-related deaths

The FDA ( Food and Drug Administration ) is aware of a potential safety issue related to Avandia ( Rosiglitazone ), a drug approved to treat type 2 diabetes. Safety data from controlled clinical trials have shown that there is a potentially significant increase in the risk of myocardial infarction ...
Read Article

Pioglitazone, a diabetes drug, shows promise for preventing brain injury from radiation therapy

Researchers at Wake Forest University School of Medicine have reported that in animal studies, a common diabetes drug prevents the memory and learning problems that cancer patients often experience after whole-brain radiation treatments. " These findings offer the promise of improving the quality...
Read Article

Increased incidence of fractures in women who received long-term treatment with Pioglitazone

Takeda Pharmaceuticals, in according to FDA ( Food and Drug Administration ) has informed healthcare providers about recent safety data concerning Pioglitazone-containing products, i.e., Actos, ActoPlus Met ( Pioglitazone and Metformin ), and Duetact ( Pioglitazone and Glimepiride ). These products ...
Read Article

Type 2 diabetes: thiazolidinediones alter levels of Necdin and E2F4

Thiazolidinediones, or glitazones, are drugs commonly prescribed to patients with type 2 diabetes. Current FDA ( Food and Drug Administration )-approved agents are known as Pioglitazone ( Actos ) and Rosiglitazone ( Avandia ). These oral agents improve blood glucose levels in people with diabetes...
Read Article